22UA:F:F-BioNTech SE (EUR)

COMMON STOCK | Biotechnology |

Last Closing

USD 105

Change

0.00 (0.00)%

Market Cap

USD 24.86B

Volume

587.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-09 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
RGO:F Regeneron Pharmaceuticals Inc

-5.60 (-0.72%)

USD 84.33B
CSJ:F CSL Limited

+0.14 (+0.08%)

USD 83.49B
CSJA:F CSL LTD SPON.ADR 2

+1.50 (+1.73%)

USD 82.40B
UNC0:F UCB S.A. UNSP.ADR 1/2

-4.00 (-4.26%)

USD 34.23B
1AE:F Argen-X

-14.40 (-2.57%)

USD 33.52B
1AEA:F argenx SE

-5.00 (-0.91%)

USD 33.15B
DUL:F Alnylam Pharmaceuticals Inc

-2.50 (-0.96%)

USD 32.23B
49BA:F BeiGene Ltd

-6.00 (-3.06%)

USD 22.99B
49B:F BeiGene Ltd.

-0.50 (-3.40%)

USD 21.35B
0QF:F Moderna Inc

+0.65 (+1.62%)

USD 16.69B

ETFs Containing 22UA:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.53% 63% D 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.53% 63% D 61% D-
Trailing 12 Months  
Capital Gain 12.93% 57% F 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.93% 57% F 55% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 38.00% 88% B+ 92% A
Dividend Return 38.00% 88% B+ 87% B+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 120.36% 10% F 9% A-
Risk Adjusted Return 31.58% 78% C+ 55% F
Market Capitalization 24.86B 99% N/A 93% A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.